Global Anti-Inflammatory Drugs Market (2022 to 2027) – Featuring AbbVie, Amgen and Biogen Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Anti-Inflammatory Drugs Market – Global Outlook & Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering.

The study considers a detailed scenario of the present global anti-inflammatory drugs market and its market dynamics for 2022?2027. It covers a detailed overview of several market growth enablers, restraints, and trends.

The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

The global anti-inflammatory drugs market is expected to grow at a CAGR of 6.78% during 2022-2027

Market Share and Segments

• Based on drug class, biologics and biosimilars is the major contributor in the global anti-inflammatory drugs market, and it is likely to witness high incremental growth of $33.64 billion during the forecast period.
• The global anti-inflammatory drugs market is highly competitive and fragmented even though the leading companies are constantly consolidating their market position through strategic and high-profile mergers and acquisitions.

Segmentation by Drug Class

• Biologics & Biosimilars
• NSAIDs
• Steroids
• Others

Segmentation by Application

• Autoimmune Diseases
• Respiratory Diseases
• Others

Segmentation by Route of Administration

• Parenteral
• Oral
• Topical
• Inhalation

Geographical Analysis

In 2021, North America was the major revenue contributor and accounted for 41.38% in the global anti-inflammatory drugs market in 2021 and witness the highest incremental growth of $20.88 billion during the forecast period.

Increasing population, the emergence of autoimmune diseases, expansion of demand, increase in pharma and biopharma facilities, and the advent of COVID-19 are major factors to boost the demand for anti-inflammatory drugs in Europe.

Market Dynamics

Opportunities & Trends

• Promising Investigational Drugs in Clinical Trial Pipelines
• Surge in Availability of Approved Biosimilars to Treat Inflammatory Diseases
• Rise in Commercialization of Anti-Inflammatory Drugs

Growth Enablers

• Preference for Anti-Inflammatory Drugs Among Patient Groups
• Rising Prevalence of Inflammatory Diseases
• Growing Use of Biologics to Treat Inflammatory Diseases

Restraints

• Patent Expiration of Anti-Inflammatory Drugs
• Side-Effects of Anti-Inflammatory Drugs
• Product Recalls Due to Stringent Regulatory Guidelines

Key Vendors

• AbbVie
• Amgen
• Biogen
• Bristol Myers Squibb
• Eli Lilly & Company
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Johnson & Johnson
• Merck & Co
• Novartis
• Pfizer

Other Prominent Vendors

• Actiza Pharmaceutical
• Allergan
• Antibe Therapeutics
• Aurinia Pharmaceuticals
• AstraZeneca
• Aurobindo Pharma
• Bayer
• Bio-Thera Solutions
• Cadila Pharmaceuticals
• Cipla
• Celltrion
• CENTURION REMEDIES
• Dr. Reddy’s Laboratories
• Eisai
• Gilead Sciences
• Glenmark Pharmaceuticals
• Lupin
• Medico Remedies
• Regeneron Pharmaceuticals
• Samsung Bioepis
• Sanofi
• Sun Pharmaceutical Industries
• Swedish Orphan Biovitrum
• UCB
• FUJIFILM KYOWA KIRIN BIOLOGICS
• Teva pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/x80wri

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900